#OncoAlertAF
LightNews LightNews
oncoalert.bsky.social
The OncoAlert #ESMO26 PULSE! 🇪🇸 WE ARE HERE!
OncoAlert would like to thank our faculty and our #OncoAlertAF
for their amazing coverage of ESMO MADRID!
WE ARE ALL OncoAlert...By Colleagues...For Colleagues

Meet our incredible faculty reporting live from Madrid:
October 25, 2026 at 3:14 PM
oncoalert.bsky.social
What if a missed cancer diagnosis could cost you 8 years of life? 🚨

On this #WeekinOncology #Melanoma by OncoAlert🚨, our #OncoAlertAF colleagues Dr. Mario Balsa 🇪🇸 discusses an article out on Nature communications

www.nature.com/articles/s41...
September 25, 2026 at 11:42 AM
oncoalert.bsky.social
The OncoAlert🚨 #WeekinOncology Continues with #Melanoma and we are proud to introduce our Expert #OncoAlertAF colleague Dr. Mario Balsa🇪🇸 to give us his pick of the most interesting article of the week.

jitc.bmj.com/content/14/9...
September 8, 2026 at 11:49 AM
oncoalert.bsky.social
Our #OncoAlertAF 🚨Colleague Nicholas Hornstein 🇺🇸 of @NorthwellHealth with TOP picks of #GIOncology Presented at #ESMO25 🇩🇪 👉 youtu.be/tVaVJ7pg50I

for the OncoAlert TOP3 Series post ESMO 2025, more to come..

✅NICHE2
✅STELLAR 303
TOP 3 Highlights in GI Oncology for #ESMO25 by Dr. Nicholas Hornstein
Our OncoAlert Faculty Dr. Nicholas Hornstein from the Northwell Health shares his Top GI Oncology picks from ESMO 2025 in Berlin, breaking down the most impactful GI trials shaping the field…
youtu.be
October 31, 2025 at 2:32 PM
oncoalert.bsky.social
Dear Colleagues
A Pleasure to introduce some our #OncoAlertAF

Associate Faculty 🚨
@elisaagostinetto.bsky.social 🇧🇪
@elisabettabonzano.bsky.social 🇮🇹
@realbowtiedoc.bsky.social 🇺🇸
@biagioricciutimd.bsky.social 🇺🇸
@weoncologists.bsky.social 🇺🇸
@drnataliagandur.bsky.social 🇦🇷
November 21, 2024 at 4:10 PM
oncoalert.bsky.social
Late-line options in metastatic #ColorectalCancer

Review offers a practical guide for oncologists using an evidence-based approach to navigate these advancements

#OncoAlertAF
@elisabettabonzano.bsky.social
@elisaagostinetto.bsky.social
@realbowtiedoc.bsky.social

https://buff.ly/3CyYOzz
November 19, 2024 at 1:28 PM
handle.invalid
Most popular sfw tags (it) in the last 60 minutes:

#photography 4
#sabcs24 4
#day3 4
#oncoalertaf 4
#italy 3
#splendidacornice 3
#masterchefit 3
#piazzapulita 3
#bigdick 2
#italia 2
December 12, 2024 at 10:54 PM
handle.invalid
Most popular sfw tags (it) in the last 60 minutes:

#sabcs24 5
#day1 5
#oncoalertaf 5
#movie 4
#filmsky 4
#moviechallenge 4
#musicsky 4
#merculedi 3
#11dicembre 3
#droghe 3
December 11, 2024 at 11:50 AM
realbowtiedoc.bsky.social
Love CanSky? Looking to stay up to date with the best in literature? Make sure you give @oncoalert.bsky.social a follow. Proud to be #OncoAlertAF
@elisabettabonzano.bsky.social
@elisaagostinetto.bsky.social
@tmprowell.bsky.social
@viveksubbiah.bsky.social
@weoncologists.bsky.social
MedSky
November 20, 2024 at 10:16 AM
kjankovic.bsky.social
🌟Exploring neoadjuvant therapy for occult #BreastCancer with axillary presentation, a retrospective study of 114 patients suggests that targeted axillary surgery may be considered instead of axillary dissection in select cases. 🌟

Read more 👉 buff.ly/3Wfs9WI
#Oncology #OncoAlertAF
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · Jan 13
Shifting from axillary dissection to targeted axillary surgery after neoadj tx

https://buff.ly/3Wfs9WI
Study explored the role of neoadjuvant systemic therapy in managing occult #BreastCancer w/ axillary presentation, which can enable less invasive surgical treatments.
January 13, 2025 at 7:22 PM
kjankovic.bsky.social
Dear colleagues,
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈

📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology

Don’t miss this unique #oncology event! 🌍👩‍⚕️👨‍⚕️

@oncoalert.bsky.social #OncoAlertAF
January 10, 2025 at 6:31 PM
kjankovic.bsky.social
⏳Delayed nephrectomy in #mRCC pts with CR/mPR after #immunotherapy shows🍀promising outcomes (48% progression-free at 29.6 months) but comes with ⬆️ surgical complexity - 65.7% cases faced challenges when tumor downsizing >10%.

👉 link.springer.com/article/10.1...

@oncoalert.bsky.social #OncoAlertAF
January 9, 2025 at 10:33 PM
kjankovic.bsky.social
🚨The @oncoalert.bsky.social Video Journal 🚨

🌟This week, our #OncoAlertAF colleague @biagioricciutimd.bsky.social guides us through his paper in @jama.com:Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer

🎥 Watch the highlights 👇
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · Jan 8
The OncoAlert Video Journal: "Deep Learning Model for Predicting Immunotherapy Response in Advanced #NSCLC Non−Small Cell #LungCancer 🫁"

This Week @biagioricciutimd.bsky.social 🇺🇸of @danafarbernews.bsky.social Guides us through his paper out on JAMA oncology

www.youtube.com/watch?v=LuD4...
OncoAlert Video Journal: Dr.Ricciuti/Deep Learning Model for Predicting IO ResponseNSCLC Lung Cancer
YouTube video by OncoAlert 360
www.youtube.com
January 8, 2025 at 2:29 PM
kjankovic.bsky.social
🆕 trial in @JournalCancer explores the feasibility of a screening program using MCED tests and whole-body MRI in high-risk populations.
✅ The findings highlight the potential for earlier detection across multiple cancer types, possibly improving outcomes. 💫
#OncoAlertAF
#CancerScreening #Oncology
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · Jan 3
Feasibility of a cancer screening program using multicancer early detection testing and whole-body magnetic resonance imaging in a high-risk population

Most participants reported reduced cancer-related worry at 6 months & overall, the testing approach was feasible

https://buff.ly/4iZrNgM
January 3, 2025 at 2:28 PM
elisabettabonzano.bsky.social
📌Advances in targeted therapies
✨ ADC 🔛🎙️ @kevinpunie.bsky.social
@oncoalert.bsky.social #OncoAlertAF #EBCC15
March 25, 2026 at 10:59 AM
elisabettabonzano.bsky.social
📌 Advances in targeted therapies
Excellent presentation on CDK4/6 ✨ by prof Nadia Harbeck ✨at #EBCC15 @oncoalert.bsky.social #OncoAlertAF
March 25, 2026 at 10:56 AM
elisabettabonzano.bsky.social
📌Advances in targeted therapies
✨Beyond Her2+ ✨ led by
@tomaspascualmd.bsky.social #EBCC15
@oncoalert.bsky.social #OncoAlertAF
March 25, 2026 at 10:54 AM
elisabettabonzano.bsky.social
📌 Primary Results From ASCENT-03 ✨

PFS: 9.7 mo vs 6.9 mo, HR 0.62
ORR: 48% vs 46%
DOR: 12.2 vs 7.2 mo
OS immature: HR 0.98
PFS2: 18.2 vs 14.0, HR 0.70

Dr. @Javier Cortès at Proffered paper session 2
#ESMO25 🇩🇪 📍Berlin
@oncoalert.bsky.social #OncoalertAF @nejm.org
🔗 lnkd.in/diBhSjXG
October 19, 2025 at 1:50 PM
elisabettabonzano.bsky.social
📌 Primary results from the randomised, phase III TROPION-Breast02 trial✨

🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291
🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001
🔸 ≥5-month improvement in both median OS and PFS

Proffered paper session 2

#ESMO25 @oncoalert.bsky.social #OncoalertAF
October 19, 2025 at 1:47 PM
elisabettabonzano.bsky.social
📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

🔗nejm.org/doi/full/10.10…

👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1)

@oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc
June 5, 2025 at 9:31 PM
elisabettabonzano.bsky.social
📌 Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?
✨Prof @icromeattini.bsky.social
👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc
June 3, 2025 at 7:26 AM
elisabettabonzano.bsky.social
📌 NRG-BR003: A randomized phase Ill trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative
TNBC.
✨Vicente Valero #ASCO25
@oncoalert.bsky.social #OncoAlertAF
June 3, 2025 at 7:24 AM
elisabettabonzano.bsky.social
📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer.
✨Erica L. Mayer, MD, MPH, FASCO
✔️Rapid Oral Abstract Session
Breast Cancer-Local/Regional/ Adjuvant
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3
June 3, 2025 at 7:23 AM
elisabettabonzano.bsky.social
📌 Highlights of the Day II
👉🏻Breast Cancer-Metastatic
✨@maryam_lustberg 👏🏻
🟩 Key takeaways HR+ MBC
🟦 Key takeaways in HER2 positive MBC
🟨 Key Takeaways Metastatic TNBC
@oncoalert.bsky.social #OncoAlertAF #ASCO25
June 3, 2025 at 7:21 AM
elisabettabonzano.bsky.social
📌 Do We "Node" What to Do About the Axilla❓
Great discussion👏🏻
✨Mediget Teshome, MD, FACS, MPH
@oncoalert.bsky.social #OncoAlertAF #ASCO25
June 3, 2025 at 7:19 AM